Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,861.85
-0.01%
DAX
26,469.92
+0.55%
CAC 40
8,746.94
+0.24%
STOXX 50
6,572.32
+0.56%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sponsored Ad Feature is produced by an advertiser with the specific intent to promote a product and is not produced by the Morning Wire team.
Friday 01 November 2024 9:29 am  |  Updated:  Tuesday 05 November 2024 9:23 am

Ananda Developments PLC

By:

Add as a preferred source on Google

Ananda is dedicated to developing medicines to treat complex, chronic inflammatory pain conditions. With 28 million people in the UK alone dealing with chronic pain and the NHS spending over £5 billion annually on musculoskeletal pain, there is a pressing need for better, more effective treatments.  In many conditions which exhibit complex, chronic inflammation and pain there is significant unmet need. 

Our patent-pending MRX1 medicine is being used in Phase II randomised controlled trials into:

  • chemotherapy induced nerve pain; and
  • endometriosis

As announced in October,  our patent-pending MRX2 and MRX2T assets are being used in two Phase IIIa randomised controlled trials into:

  • refractory (drug-resistant) early onset epilepsies; and
  • refractory genetic generalised epilepsies

Meet the team

Jeremy Sturgess-Smith – Finance Director – Jeremy Sturgess-Smith is a finance leader with a proven track record in corporate finance, investor relations, and strategic growth. As the first employee and a co-founder of Ananda Developments plc, Jeremy played a pivotal role in the company’s inception and spearheaded its successful IPO in July 2018. He also led the acquisitions of MRX Medical Limited, a company running two phase III studies in partnership with University College London and two phase II clinical trials in partnership with the University of Edinburgh. Beyond managing the Ananda Group’s corporate finance, audit processes, and investor relations, he oversees IT and HR as well. 

Jeremy was also a core team member of the successful IPO of URA Holdings plc in 2022 and its acquisition of the historic Gravelotte emerald mine in 2023 and Curlew Emerald Project in 2024.

LinkedIn

Ananda Developments PLC will be presenting at the 2024 Aquis Showcase

Ananda Developments PLC is proud to be a part of the 2024 Aquis Showcase, a premier event that introduces high-potential growth companies to retail investors. This event provides a valuable platform for innovative businesses like Ananda to connect with investors looking for the next generation of market leaders.

At the 2024 Aquis Showcase, Ananda Developments PLC are excited to connect with retail investors, Providing insights into its innovative solutions and the significant impact they create for businesses. The company looks forward to presenting its future growth plans and demonstrating its unwavering commitment to service excellence and sustainable success.

Learn more: https://www.aquis.eu/companies/ANA

Read more

Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Markets & Economics

Categories

  • Sponsored

Related Topics

  • Capital Markets
  • London business
  • Markets
  • Private markets
  • stock exchange

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

    Business Wire
  • Oil price falls but Trump and Iran clash on negotiations claim

    Markets
    Donald Trump smiling in a blue suit and tie with an American flag pin, US flag in background
  • A photography expert’s guide to the best images from the World Cup

    Sport Business
    Action shot of a player competing in the 2107 World Cup soccer tournament.
  • In praise of Count Binface

    Opinion
    Count Binface wearing a silver mask and cape, standing in front of a podium during a press conference.
  • HoneyBook Expands Platform with New Features for Photographers

    Business Wire
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • ustwo brings AI governance to the boardroom with appointment of Google DeepMind executive Simon Bouton

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook